Simulations Plus shareholders will receive $18.50 per share in cash. This deal values the company at $375 million, according to Fierce Biotech. The acquisition by Altaris Capital offers a 26% premium to Simulations Plus's recent average price as of June 15, 2026. The all-cash transaction provides immediate liquidity for investors.
Simulations Plus built a reputation for independent innovation in drug discovery software. However, its acquisition by Altaris Capital marks a strategic shift towards private equity-driven growth, potentially altering the company's long-standing research and development priorities.
The life sciences software sector will likely see further consolidation as private equity firms capitalize on specialized tools driving pharmaceutical R&D efficiency. Aggressive financial backing now appears essential for scaling, even for established innovative companies.
The Deal at a Glance
- Simulations Plus, Inc. announced a definitive agreement for acquisition by Altaris, LLC in an all-cash deal valuing the company at approximately $375 million, according to TipRanks.
- Altaris, through its affiliates SP Evolution HoldCo II, LLC and SP Evolution BidCo II, LLC, will acquire Simulations Plus, Inc. in a merger, reports Stock Titan.
- The acquisition price is $18.50 per share, as reported by Investing.
- Benzinga also reports the acquisition of Simulations Plus by Altaris is valued at approximately $375 million.
The formal agreement and specific acquiring entities confirm a structured private equity takeover. This meticulous structuring suggests Altaris's intent to rapidly operationalize its investment and leverage Simulations Plus's assets within a broader portfolio strategy.
A Significant Premium for Shareholders
The deal values Simulations Plus at $375 million, a 26% premium to its 60-day volume-weighted average price as of June 15, 2026, according to TipRanks. Stockholders will receive $18.50 per share in cash. This valuation confirms Altaris Capital's conviction in the company's future value.
The substantial premium underscores Altaris's confidence in Simulations Plus's market position and future growth potential. It provides a highly favorable exit for current shareholders, offering immediate and significant returns.
Broader Market Implications
The acquisition aligns with a broader trend of private equity firms targeting specialized software companies. These firms seek critical tools that enhance efficiency in complex industries like pharmaceuticals. The Altaris Capital acquisition of Simulations Plus in 2026 exemplifies this strategy.
The all-cash deal suggests Altaris expects to generate substantial returns quickly. This approach often involves operational efficiencies or aggressive market penetration, rather than relying on stock performance. Companies in niche, high-value tech sectors should brace for increased private equity interest.
What's Next for Simulations Plus?
Under Altaris's ownership, Simulations Plus will likely focus on accelerated growth and market expansion, potentially through further acquisitions or strategic partnerships. This private equity backing could provide resources for faster development cycles and broader market reach. This shift suggests specialized software developers may increasingly trade autonomy for capital, likely impacting R&D priorities and accelerating market consolidation.
Frequently Asked Questions
What does Simulations Plus do?
Simulations Plus develops software for drug discovery and development. Its key products include GastroPlus, which simulates drug absorption and distribution, and ADMET Predictor, used for predicting molecular properties. These tools assist pharmaceutical companies in optimizing drug candidates and reducing development costs.
Who is Altaris Capital?
Altaris Capital is a healthcare-focused private equity firm based in New York. The firm specializes in control investments in middle-market healthcare companies. Altaris targets businesses with strong growth potential, aiming to enhance their value through operational improvements and strategic expansion.
What is the impact of the Altaris Capital acquisition of Simulations Plus?
The acquisition is expected to accelerate Simulations Plus's market penetration and potentially expand its product offerings. Altaris Capital's financial backing may lead to increased investment in new technologies or strategic acquisitions. This could shift the company's focus towards more rapid, market-driven growth strategies.
